Flow Cytometric Assay of c-erbB-2 Protein in Fine Needle Aspirates of Fresh and Frozen Human Breast Cancer Tissues

[1]  S. Ménard,et al.  Prognosis based on primary breast carcinoma instead of pathological nodal status. , 1994, British Journal of Cancer.

[2]  P. Lipponen,et al.  Expression of E‐cadherin (E‐CD) as related to other prognostic factors and survival in breast cancer , 1994, The Journal of pathology.

[3]  M. Noguchi,et al.  Immunohistochemical detection of p53 and c-erbB-2 proteins: Prognostic significance in operable breast cancer , 1994, Breast cancer.

[4]  T. Akiyama,et al.  Construction of Immunoradiometric Assay for Circulating c‐erbB‐2 Protooncogene Product in Advanced Breast Cancer Patients , 1993, Japanese journal of cancer research : Gann.

[5]  H. Magdelenat,et al.  Immunocytochemical determination of estrogen and progesterone receptors on 50 fine-needle samples of breast cancer. A prospective study including biochemical correlation and DNA flow cytometric analysis. , 1992, American journal of clinical pathology.

[6]  C. Redmond,et al.  DNA flow cytometric analysis of primary operable breast cancer. Relation of ploidy and S‐Phase fraction to outcome of patients in NSABP B‐04 , 1991, Cancer.

[7]  H. Magdelenat,et al.  Breast cancer proliferation measured on cytological samples: a study by flow cytometry of S-phase fractions and BrdU incorporation. , 1991, British Journal of Cancer.

[8]  A. Givan,et al.  Node negative breast cancer: The prognostic value of DNA ploidy for long‐term survival , 1991, The British journal of surgery.

[9]  A. Harris,et al.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.

[10]  J. Winstanley,et al.  The long term prognostic significance of c-erbB-2 in primary breast cancer. , 1991, British Journal of Cancer.

[11]  J. Bártková,et al.  The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. , 1991, British Journal of Cancer.

[12]  R. Abe,et al.  [Flow cytometric DNA analysis using fine needle aspiration sample in breast cancer: preliminary report]. , 1991, Nihon Geka Gakkai zasshi.

[13]  T Nakamura,et al.  Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer , 1990, Cancer.

[14]  T. Akiyama,et al.  In vitro and in vivo Release of Soluble erbB‐2 Protein from Human Carcinoma Cells , 1990, Japanese journal of cancer research : Gann.

[15]  S. Mori,et al.  Association of Elevated Expression of the c‐erbB‐2 Protein with Spread of Breast Cancer , 1989, Japanese journal of cancer research : Gann.

[16]  D. Altman,et al.  An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. , 1988, British Journal of Cancer.

[17]  A. Howell,et al.  Effect of tamoxifen upon cell DNA analysis by flow cytometry in primary carcinoma of the breast. , 1987, British Journal of Cancer.

[18]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[19]  N. Nomura,et al.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.

[20]  R. Weinberg,et al.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.

[21]  F. Hirsch,et al.  Treatment of small-cell carcinoma of the lung monitored by sequential flow cytometric DNA analysis. , 1982, Cancer research.

[22]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[23]  I. Olivotto,et al.  The use of sequential fine-needle aspiration biopsy with flow cytometry to monitor radiation induced changes in breast carcinoma. , 1992, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[24]  P. Quirke,et al.  Quantitation by flow cytofluorometry of response of tumours of the uterine cervix to radiotherapy. , 1985, The British journal of radiology.